Use of mildronate in therapy of seroresistant syphilis (serologic and immunologic comparisons

Clinico-serological and immunological examinations were applied to 84 patients suffering from seroresistant syphilis with positive serological reactions within 1.5 to 10 years after termination of the treatment by various methods. The initial diagnosis of recently inflicted secondary syphilis was recorded in 8.9 per cent of the patients. 43.3 and 47.8 per cent of the patients had secondary relapsing syphilis and early occult syphilis, respectively. The percentage of lymphocytes CD3+, CD4+, CD8+ and HLA DR+ was determined in peripheric blood with the monoclonal antibodies OKT-3+, OKT-4+, OKT-8+ and FITC-labeled antimouse Ig. The quantity of IgA, IgG and IgM was determined by radial immunodiffusion. The immunoregulatory index (IRI, the ratio of T-helper/inductor cells and T-suppressor cells/cytotoxics) was calculated. The use of mildronate, a drug developed at the Institute of Organic Chemistry of the Academy of Sciences of the Latvian SSR (Riga), led to normalization of the impaired immunological indices and complete negativation of the serological reactions in the group of the patients with disorders in the immunity status (CD8+ - 33 per cent and IRI - 1.3), p less than 0.01.     

Cerebral organization of verbal action in stutterers

A comprehensive interdisciplinary study of the cerebral mechanisms of readiness for speech was performed based on a complete neuropsychological examination according to A.R. Luria with qualification and quantification of the detected symptoms and electrophysiological data by an original method of recording and localization of the potentials synchronized with the preparation for speaking. The data on stutterers were compared with those on normal subjects and showed that stuttering is not an isolated (purely peripheral) speech disorder but is a component of a syndrome consisting of specific mnestic, neurodynamic, and motor defects that reflect dysfunction of postfrontal and median structures of the brain (functional blocks I and III according to Luria). Differences between normal and stuttering subjects in the potential related to readiness for speech were associated with the activity of deep median structures (the pons and brainstem), right subcortical nuclei, the right frontal cortex, and the left mediotemporal cortex.Translated from Fiziologiya Cheloveka, Vol. 31, No. 2, 2005, pp. 13–17.Original Russian Text Copyright © 2005 by Vartanov, Glozman, Kiselnikov, Karpova.     

Inhibition of Oncogenic and Activated Wild-Type ras-p21 Protein-Induced Oocyte Maturation by Peptides from the ras-Binding Domain of the raf-p74 Protein, Identified from Molecular Dynamics Calculations

In the preceding paper we found from molecular dynamics calculations that the structure of the ras-binding domain (RBD) of raf changes predominantly in three regions depending upon whether it binds to ras-p21 protein or to its inhibitor protein, rap-1A. These three regions of the RBD involve residues from the protein–protein interaction interface, e.g., between residues 60 and 72, residues 97–110, and 111–121. Since the rap-1A–RBD complex is inactive, these three regions are implicated in ras-p21-induced activation of raf. We have therefore co-microinjected peptides corresponding to these three regions, 62–76, 97–110, and 111–121, into oocytes with oncogenic p21 and microinjected them into oocytes incubated in in insulin, which activates normal p2l. All three peptides, but not a control peptide, strongly inhibit both oncogenic p21- and insulin-induced oocyte maturation. These findings corroborate our conclusions from the theoretical results that these three regions constitute raf effector domains. Since the 97–110 peptide is the strongest inhibitor of oncogenic p21, while the 111–121 peptide is the strongest inhibitor of insulin-induced oocyte maturation, the possibility exists that oncogenic and activated normal p21 proteins interact differently with the RBD of raf.     

Docosahexaenoic acid-deficient phosphatidyl serine and high alpha-tocopherol in a fetal mouse brain over-expressing Cu/Zn-superoxide dismutase

The over-expressed Cu/Zn-superoxide dismutase (Cu/Zn-SOD) gene has been found in some circumstances phenotypically deleterious and associated with oxidative injury-mediated aberrations while in other studies it was considered neuroprotective. In this work we examine a number of biochemical markers in fetal and adult brain from transgenic (tg) mice expressing the human Cu/Zn-SOD gene, which may determine this dual characteristic. These markers include the polyunsaturated fatty acid (PUFA) profile in discrete phospholipid species, the alpha-tocopherol levels, a marker for lipid anti-oxidant status, and thiobarbituric acid reactive substance (TBARS), a marker for the tissue oxidative status. The PUFA profile in choline- and ethanolamine-phosphoglycerides was similar in tg and nontransgenic (ntg) animals of either fetal or adult brain. Serine-phosphoglycerides, however, showed a marked decrease from 20. 07+/-0.53 to 14.92+/-0.87 wt% and 14.52+/-1.15 wt% in docosahexaenoic acid (DHA; 22:6 n3), in the tg 51 and tg 69 fetal brains, respectively, but not in the comparable adult tissues. The alpha-tocopherol levels were significantly higher in the fetal compared to the adult brain. There were no differences in the anti-oxidant levels between the ntg and tg fetal brains, but there were differences in the adult animals; the tg mice were higher by at least two-fold than the control animals. The basal TBARS in the tg 51 fetal brain was 35% lower than that of ntg mouse and in the presence of Fe(2+), brain slices from the former released less TBARS (57% reduction) into the medium than the latter. These results suggest that higher dosages of Cu/Zn-SOD gene are compatible with increased alpha-tocopherol levels, reduced basal TBARS levels and a DHA deficiency in the fetal, but not the adult, tg brain.     

The autophagy-associated Atg8 gene family operates both under favourable growth conditions and under starvation stresses in Arabidopsis plants

Arabidopsis plants possess a family of nine AtAtg8 gene homologues of the yeast autophagy-associated Apg8/Aut7 gene. To gain insight into how these genes function in plants, first, the expression patterns of five AtAtg8 homologues were analysed in young Arabidopsis plants grown under favourable growth conditions or following exposure to prolonged darkness or sugar starvation. Promoters, plus the entire coding regions (exons and introns) of the AtAtg8 genes, were fused to the beta-glucuronidase reporter gene and transformed into Arabidopsis plants. In all plants, grown under favourable growth conditions, beta-glucuronidase staining was much more significant in roots than in shoots. Different genes showed distinct spatial and temporal expression patterns in roots. In some transgenic plants, beta-glucuronidase staining in leaves was induced by prolonged darkness or sugar starvation. Next, Arabidopsis plants were transformed with chimeric gene-encoding Atg8f protein fused to N-terminal green fluorescent protein and C-terminal haemagglutinin epitope tags. Analysis of these plants showed that, under favourable growth conditions, the Atg8f protein is efficiently processed and is localized to autophagosome-resembling structures, both in the cytosol and in the central vacuole, in a similar manner to its processing and localization under starvation stresses. Moreover, treatment with a cocktail of proteasome inhibitors did not prevent the turnover of this protein, implying that its turnover takes place in the vacuoles, as occurs in yeasts. The results suggest that, in plants, the cellular processes involving the Atg8 genes function efficiently in young, non-senescing tissues, both under favourable growth conditions and under starvation stresses.     

Pharmacological characteristics of a new phenyl analog of piracetam--4-phenylpiracetam

The central neurotropic effects of 4-phenylpyracetam, a new phenyl analog of pyracetam, were studied and compared with the effects of pyracetam, morpholene and 4-phenylpyrrolidone. 4-Phenylpyracetam was found to activate the operant behavior more powerfully, to remove psychodepressant effects of diazepam, to inhibit post-rotational nystagmus, and to prevent the development of retrograde amnesia. Unlike pyracetam, 4-phenylpyracetam exhibits a specific anticonvulsant action. When given in high doses, the compound under study produces psychodepressant effects.     

Intraamniotic Ethyl Docosahexaenoate Administration Protects Fetal Rat Brain from Ischemic Stress

Abstract: Studies were conducted on the prenatal rat given a single intraamniotic injection of ethyl docosahexaenoate (Et-DHA; 9.6–12 mmol per fetus) or subjected to an n-3 fatty acid-deficient diet to assess the role of docosahexaenoate on oxidative stress during episodes of ischemia. A time-dependent decrease in the ability of brain slices from animals treated with Et-DHA to produce thiobarbituric acid-reactive substance (TBARS), most pronounced after 1 day (from 58.1 ± 4.22 to 15.9 ± 1.6 nmol/mg of DNA), was noticed on stimulation with Fe²⁺. Brain slices from fetuses treated for 1 day with Et-DHA and those from untreated fetuses produced TBARS levels of 46.7 ± 6.5 and 114.8 ± 10.8 nmol/mg of DNA, respectively, after a 20-min occlusion of the fetal-maternal circulation at embryonic day 20, suggesting a protective effect of Et-DHA. The protective effect of a single dose of Et-DHA in utero remained high up to 3 days after injection ( p < 0.001) and was long-lasting, yet not significant, up to 3 days following birth. In agreement with a reduction in TBARS production by slices, the endogenous levels of TBARS in brains of Et-DHA-treated animals were lower than in the controls. Et-DHA-injected fetuses exhibited significantly higher levels of esterified DHA than the non-injected controls. n-3-deficient diet given to dams for 2 weeks before birth did not affect the levels of TBARS production in control fetal brain slices but abolished the increase caused by ischemia. Et-DHA administration for 24 h to n-3-deficient fetuses reduced the amount of TBARS produced by the fetal brain slices from 49.1 ± 8.5 to 31.7 ± 4.1 nmol/mg of DNA. A protective effect from oxidative damage after postischemic oxidative stress in fetal brain following DHA supplements is suggested, whereas the effect of n-3 fatty acid deficiency in this regard is more ambiguous.     

Immunologic foundation of enzyme therapy of patients with orchiepididymitis

Twenty eight patients aged 18 to 40 years with urogenital infections complicated by orchiepididymitis were examined immunologically. The use of specific monoclonal antibodies OKT-4+ and OKT-8 revealed lower contents of T-helper cells (Thc) (23.33 +/- 9.7%) and higher contents of T-suppressor cells (Tsc) (41.17 +/- 13.41%) in them as compared to those in healthy volunteers (18 persons) and patients with noncomplicated urogenital infections (19 persons). There was a significant decrease in the immunoregulatory index (IRI): Thc/Tsc (0.68 +/- 0.33) reached in some patients the ratio observed in persons infected with the HIV (0.6 +/- 0.2) and an increase in the contents of circulating immune complexes (CIC) (28.5 +/- 2.0 arbitrary units against the normal of 10.0 +/- 0.7). Enzyme therapy including the use of chymotrypsin and trypsin manufactured in the USSR in doses of 10 mg each administered intramuscularly once a day or in doses of 5 mg each administered intramuscularly twice a day for 10 days promoted normalization of the impaired immunity indices (Thc 44.0 +/- 10.51%, Tsc 31.5 +/- 11.26%, IRI 1.53 +/- 0.33 and CIC 12.1 +/- 0.74 arbitrary units). Therefore, the enzymes had an immunomodulating effect. It is likely that they will be useful in treatment of infectious inflammatory processes accompanied by analogous immune disorders which makes the enzyme immunocorrection more applicable in treatment of various pathological processes.